MedTrace Logo

Antibiotic Dosing in Patients on Intermittent Hemodialysis

NCT03909698 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2022-11-29

No results posted yet for this study

Summary

The adequacy of the currently used dosing regimen of glycopeptides (vancomycin and teicoplanin) and beta-lactam antibiotics (amoxicillin-clavulanic acid, piperacillin-tazobactam, ceftazidim) in patients with end-stage kidney disease receiving intermittent hemodialysis is studied by evaluating pharmacokinetics-pharmacodynamics (PK-PD) target attainment. A population pharmacokinetic study is performed to assist the selection of the optimal individualized dose for patients undergoing intermittent dialysis, taking into consideration as many relevant variables as possible.

Conditions

  • Kidney Failure, Chronic
  • Antibiotics
  • Hemodialysis

Interventions

OTHER

Blood and urine sampling

During a period of maximum 6 days blood is sampled at different time points and urine is collected during documented time intervals.

Sponsors & Collaborators

  • University Ghent

    collaborator OTHER

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Wim Van Biesen, PhD, MD · University Hospital, Ghent

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-15
Primary Completion
2022-03-31
Completion
2022-03-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03909698 on ClinicalTrials.gov